Full Breakdown
Supreme Court Restores Mifepristone Telemedicine Access Amid Trump Administration Silence
5/19/2026, 2:35:02 AM
Supreme Court Restores Mifepristone Telemedicine Access
The Supreme Court reinstated telemedicine and mail access for mifepristone after a federal appeals court temporarily blocked the policy following a Louisiana lawsuit. The Justice Department declined to brief the Court, leaving the case pending.
Legal Landscape After Roe v. Wade Overturn
The 2022 Supreme Court decision overturning Roe v. Wade ended the constitutional right to abortion. Abortions remain widely available, with a slight rise linked to the abortion pill mifepristone. The FDA, under a Biden-era rule, permits telemedicine and mail prescriptions of the pill.
Chronology of the Litigation
2022 – Supreme Court overturns Roe v. Wade.
2026 – Midterm elections approach, increasing Republican pressure.
May 2026 – Louisiana sues the FDA; a federal appeals court temporarily blocks telemedicine and mail distribution of mifepristone.
Early May 2026 – Supreme Court pauses the ruling twice.
Late May 2026 – Supreme Court restores telemedicine and mail access as lower-court litigation proceeds.
Abortion Rates Since 2022
Abortions per year have risen slightly since 2022, a trend linked to the abortion pill mifepristone.
Political Stakes and Public-Health Implications
The case puts the Trump administration in a political bind, with abortion a polarizing issue before the 2026 midterms. The Justice Department’s refusal to defend the FDA may aim to avoid alienating both pro-life voters and reproductive-health advocates. The Supreme Court’s temporary restoration of telemedicine access preserves a patient pathway for medication without in-person visits, shaping public health and legal precedent.
Administration’s Public Position
President Donald Trump has not commented publicly. The Justice Department declined to file a brief, an action the administration characterized as atypical. Former HHS general counsel Samuel Bagenstos criticized the silence, noting the agencies most directly affected failed to appear before the Supreme Court.
Legal Experts Criticize Department’s Inaction
Samuel Bagenstos called the Justice Department’s non-participation “shocking,” noting agencies most directly impacted failed to defend the policy. He said the situation reflects a “very difficult political position” for the administration.
Unanswered Questions
The Trump administration has offered no explanation for the Justice Department’s inaction. Exact abortion-rate figures since 2022 are unavailable. Details of the lower-court litigation remain pending.
Key Direct Quotes
- “That they’re the folks who are most directly affected by the litigation and they’re not filing anything — that is shocking.” — Samuel Bagenstos, former General Counsel, U.S. Department of Health and Human Services
- “I think it reflects this very difficult political position that the Trump administration is in.” — Samuel Bagenstos, former General Counsel, U.S. Department of Health and Human Services
- “the most pro-life president in history.” — Donald Trump, President of the United States
- “highly unusual.” — The New York Times, news outlet
Future Developments
The case will continue in lower federal courts, while the 2026 midterm elections loom. The Supreme Court may revisit the issue if further appeals arise.
